Skip to main content

Table 3 Summary of studies on suPAR related to treatment response in nephrotic syndrome

From: Soluble urokinase plasminogen activator receptor (suPAR) and glomerular disease in children: a narrative review

Year Study N. cases Patient population suPAR (pg/ml) Comments
2014 Peng et al. [30] 176 176 children (69.3% male).
Mean age: 19–191 months old.
108 steroid-sensitive NS (SSNS), 68 steroid-resistant NS (SRNS)
Serum suPAR in SSNS was 3744.1 ± 2226.0 compared with SRNS was 2153.5 ± 1167.0 (i) There is a significant difference in serum suPAR between SSNS and SRNS, p < 0.05.
(ii) AUC was 0.80, with p <0.001 to predict SRNS. The suPAR concentration to predict SRNS was estimated to be 1907.0 pg/ml to 3043.5 pg/ml (χ2 = 14,775, p=0.001).
2018 Mousa et al. [31] 75 Mean age: 7.9 ± 4.2 years old
25 SSNS, 25 steroid-dependent NS (SDNS) and 25 SRNS and 40 controls
SRNS: (66.52 ± 9.7 ng/mL), SDNS: (56.82 ± 11.09 ng/L), SSNS: (26.22 ± 3.86 ng/mL), and controls: (20.29 ± 0.69 ng/mL). (i) There was a significant difference between the treatment response groups of NS with p<0.01
(ii) AUC of suPAR in predicting SDNS was 0.99 with p <0.001. A suPAR concentration > 32.4 ng/mL was the best cutoff for 96% sensitivity and specificity. Meanwhile, the AUC of suPAR in predicting SRNS was 1.00 with p <0.001. A suPAR concentration >33.17 ng/mL was the best cutoff with a sensitivity and specificity of 100%.